MENU
+Compare
INNPF
Stock ticker: OTC
AS OF
Dec 9 closing price
Price
$0.16
Change
-$0.00 (-0.00%)
Capitalization
86.96M

INNPF stock forecast, quote, news & analysis

INNPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
A.I.Advisor
a Summary for INNPF with price predictions
Dec 18, 2024

INNPF in -3.66% downward trend, sliding for three consecutive days on December 18, 2024

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where INNPF declined for three days, in of 57 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Momentum Indicator moved below the 0 level on December 18, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on INNPF as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where INNPF's RSI Oscillator exited the oversold zone, of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for INNPF just turned positive on December 12, 2024. Looking at past instances where INNPF's MACD turned positive, the stock continued to rise in of 36 cases over the following month. The odds of a continued upward trend are .

INNPF moved above its 50-day moving average on December 10, 2024 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for INNPF crossed bullishly above the 50-day moving average on December 17, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +13,80 3-day Advance, the price is estimated to grow further. Considering data from situations where INNPF advanced for three days, in of 56 cases, the price rose further within the following month. The odds of a continued upward trend are .

INNPF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 62 cases where INNPF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.406) is normal, around the industry mean (57.958). P/E Ratio (0.000) is within average values for comparable stocks, (89.727). INNPF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.947). Dividend Yield (0.074) settles around the average of (0.122) among similar stocks. INNPF's P/S Ratio (208.333) is very high in comparison to the industry average of (19.472).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. INNPF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INNPF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

A.I.Advisor
published Dividends

INNPF paid dividends on November 29, 2024

Innocan Pharma Corp. INNPF Stock Dividends
А dividend of $0.37 per share was paid with a record date of November 29, 2024, and an ex-dividend date of November 15, 2024. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 3.53B. The market cap for tickers in the group ranges from 246 to 77.48B. ZTS holds the highest valuation in this group at 77.48B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 1%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was -9%. SEHCD experienced the highest price growth at 718%, while FLGC experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 2%. For the same stocks of the Industry, the average monthly volume growth was 23% and the average quarterly volume growth was 1%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 56
P/E Growth Rating: 70
Price Growth Rating: 64
SMR Rating: 84
Profit Risk Rating: 91
Seasonality Score: 34 (-100 ... +100)
View a ticker or compare two or three
INNPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
N/A
Address
13215 Bee Cave Parkway
Phone
+1 512 538-2300
Employees
78
Web
https://www.shpreit.com